Physicians' Academy for Cardiovascular Education

Challenges for screening and treatment of FH patients in clinical cardiology

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME

Video navigation menu

  • Where do we stand with respect to FH in clinical cardiology? 00:18
  • What can be done to increase finding FH in ACS? 02:36
  • Who should be screened and how to diagnose? 04:20

Educational information

This video was recorded during an expert meeting among cardiologists and internists, focussing on the topic of 'LDL-c & PCSK9 inhibition in high CV risk patients - Balancing Science, Guidelines and Daily Cardiology Practice'.

The objectives of the meeting were to:

Other topics covered in this series

Other lectures part of this educational series are:

Faculty

Prof. Kausik Ray, MD - cardiologist, Imperial College London, United Kingdom

Prof. Kees Hovingh, MD - Internist and vascular medicine specialist at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, the Netherlands and visiting professor at Imperial college in London, UK

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Funding for the Expert Meeting was provided by an unrestricted educational grant from Amgen. The sponsor did not attend and influence the video recording.

Online-CME

This is available as accredited online CME for members. Click the button below to enroll:

Enroll
The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: